Prime Medicine reports positive initial Phase 1/2 trial results for PM359, showing safety and efficacy in treating Chronic Granulomatous Disease. Prime Medicine, Inc. has announced positive initial ...
The changing natural and social environments, coupled with pathogen mutations, have led to a spike in the emergence of new infectious diseases. This presents a severe medical challenge for the world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results